Immunovant Stock Fundamentals
| IMVT Stock | USD 26.87 0.33 1.24% |
Immunovant fundamentals help investors to digest information that contributes to Immunovant's financial success or failures. It also enables traders to predict the movement of Immunovant Stock. The fundamental analysis module provides a way to measure Immunovant's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunovant stock.
At this time, Immunovant's Other Operating Expenses is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to about 25.1 M in 2024, despite the fact that Operating Income is likely to grow to (450.00). Immunovant | Select Account or Indicator |
Immunovant Company Current Valuation Analysis
Immunovant's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Immunovant Current Valuation | 3.42 B |
Most of Immunovant's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunovant is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Immunovant Current Valuation Historical Pattern
Today, most investors in Immunovant Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immunovant's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Immunovant current valuation as a starting point in their analysis.
Immunovant Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Immunovant has a Current Valuation of 3.42 B. This is 76.17% lower than that of the Biotechnology sector and 26.32% lower than that of the Health Care industry. The current valuation for all United States stocks is 79.41% higher than that of the company.
Immunovant Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immunovant's current stock value. Our valuation model uses many indicators to compare Immunovant value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunovant competition to find correlations between indicators driving Immunovant's intrinsic value. More Info.Immunovant is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Immunovant's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Immunovant by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Immunovant Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunovant's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunovant could also be used in its relative valuation, which is a method of valuing Immunovant by comparing valuation metrics of similar companies.Immunovant is currently under evaluation in current valuation category among its peers.
Immunovant ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunovant's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunovant's managers, analysts, and investors.Environmental | Governance | Social |
Immunovant Fundamentals
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.55 | ||||
| Current Valuation | 3.42 B | ||||
| Shares Outstanding | 146.78 M | ||||
| Shares Owned By Insiders | 55.64 % | ||||
| Shares Owned By Institutions | 54.57 % | ||||
| Number Of Shares Shorted | 13.1 M | ||||
| Price To Book | 8.68 X | ||||
| EBITDA | (269.98 M) | ||||
| Net Income | (259.34 M) | ||||
| Cash And Equivalents | 427.2 M | ||||
| Cash Per Share | 3.66 X | ||||
| Total Debt | 138 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 21.48 X | ||||
| Book Value Per Share | 3.06 X | ||||
| Cash Flow From Operations | (214.23 M) | ||||
| Short Ratio | 19.69 X | ||||
| Earnings Per Share | (2.21) X | ||||
| Target Price | 48.93 | ||||
| Number Of Employees | 207 | ||||
| Beta | 0.71 | ||||
| Market Capitalization | 3.9 B | ||||
| Total Asset | 666.37 M | ||||
| Retained Earnings | (825.68 M) | ||||
| Working Capital | 617.16 M | ||||
| Net Asset | 666.37 M |
About Immunovant Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunovant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunovant using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunovant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -24 M | -22.8 M | |
| Cost Of Revenue | 231 K | 219.4 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.